Variables | All | HR for treatment discontinuation | 95% CI | P-value | ||
---|---|---|---|---|---|---|
Sociodemographic and clinical characteristics | ||||||
Sex, n (%) males | 67 (86%) | 1.165 | 0.397–3.413 | 0.781 | ||
Ethnicity, n (%) Jewish | 62 (79%) | 0.864 | 0.294–2.544 | 0.791 | ||
Age at diagnosis in months (mean ± SD) | 34.3+-15.6 | 0.875 | 0.618–1.239 | 0.452 | ||
ADOS-2 comparison score (mean ± SD) | 7.4+-2.2 | 1.071 | 0.875–1.312 | 0.505 | ||
DSM-5 severity level (A criteria), n (%) | Requiring support | 0 (0%) | 0.539 | |||
Requiring substantial support | 36 (46%) | 0.238–1.218 | 0.137 | |||
Requiring very substantial support | 39 (50%) | |||||
DSM-5 severity level (B criteria), n (%) | Requiring support | 4 (5%) | ||||
Requiring substantial support | 35 (45%) | 1.060 | 0.457–2.458 | 0.892 | ||
Requiring very substantial support | 36 (46%) | |||||
PLS score (mean ± SD) | 63.2+-24.3 | 0.995 | 0.975–1.015 | 0.642 | ||
Cognitive score (mean ± SD) | 71.9+-18 | 1.020 | 0.993–1.047 | 0.150 | ||
ABAS GAC score (mean ± SD) | 57.3 +-10.3 | 0.992 | 0.929–1.060 | 0.820 | ||
Any medical comorbidity, n (%) | 38 (49%) | 0.669 | 0.293–1.530 | 0.341 | ||
Any neuro-developmental comorbidity,a n (%) | 9 (11%) | 1.162 | 0.345–3.909 | 0.809 | ||
Any emotional-behavioral comorbidity,b n (%) | 7 (9%) | 0.038 | 0.000-6.811 | 0.217 | ||
ADHD, n (%) | 25 (32%) | 0.605 | 0.245–1.494 | 0.276 | ||
Any other psychoactive medications,c n (%) | 37 (47%) | 0.452 | 0.194–1.052 | 0.066 | ||
Antipsychotic medications, n (%) | 19 (24%) | 0.729 | 0.272–1.955 | 0.530 | ||
Stimulant medications, n (%) | 15 (19%) | 0.796 | 0.291–2.178 | 0.657 | ||
Treatment characteristics | ||||||
Age at treatment beginning in months (mean±SD) | 51.9 (+-20) | 1.118 | 0.890–1.404 | 0.336 | ||
Final dosage in mg (mean±SD) | 3.98 (+-2.7) | 0.920 | 0.769–1.102 | 0.367 | ||
Treatment course | Times per week (mean±SD) | 6.3 (+-1.5) | 1.385 | 0.843–2.276 | 0.199 | |
Continuity (no cessation of more than several days), n (%) | 63 (81%) | 1.798 | 0.535–6.040 | 0.342 | ||
Source of medication—imported, as dietary supplement, n (%) | 14 (18%) | 0.490 | 0.145–1.656 | 0.251 | ||
Any side effects, n (%) | 11 (14%) | 1.919 | 0.710–5.188 | 0.199 |